sorafenib has been researched along with Adenocarcinoma, Follicular in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Alevizaki, M; Karapanou, O; Saltiki, K; Simeakis, G; Vlassopoulou, B | 1 |
| Baxi, SS; Cullen, G; Dunn, LA; Fagin, JA; Fury, MG; Ghossein, RA; Haque, S; Ho, AL; Pfister, DG; Sherman, EJ; Sima, CS | 1 |
| García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y | 1 |
| Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN | 1 |
| Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F | 1 |
| de la Fouchardiere, C | 1 |
| Lohse, AW; Schramm, C; Schuch, G | 1 |
| Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K | 1 |
| Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
| Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L | 1 |
| Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S | 1 |
| Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R | 1 |
| Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW | 1 |
1 review(s) available for sorafenib and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives.
Topics: Adenocarcinoma, Follicular; Humans; Iodine Radioisotopes; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2022 |
5 trial(s) available for sorafenib and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Radiation Tolerance; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2017 |
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss | 2015 |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2009 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2011 |
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
11 other study(ies) available for sorafenib and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pleural Effusion, Malignant; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2014 |
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2014 |
[Lenvatinib in radioiodine refractory thyroid carcinomas].
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trials; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2016 |
Sorafenib-induced liver failure.
Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Failure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
A painful cranial bulge.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |